Related Experiment Videos
Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption
Cancer Chemotherapy and Pharmacology
|January 1, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2018
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Alternative methodological approach to randomized trial for surgical procedures routinely used.
Contemporary clinical trials·2018
Choosing a career in oncology: results of a nationwide cross-sectional study.
BMC medical education·2018
Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders.
Cancer chemotherapy and pharmacology·2026
Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.
Cancer chemotherapy and pharmacology·2026
Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients.
Cancer chemotherapy and pharmacology·2026
Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.
Cancer chemotherapy and pharmacology·2026
CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.
Cancer chemotherapy and pharmacology·2026
Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
Cancer chemotherapy and pharmacology·2026